Other News To Note
Tuesday, December 21, 2010
PDL BioPharma Inc., of Incline Village, Nev., said the U.S. Patent and Trademark Office terminated an interference proceeding initiated by UCB Pharma SA, of Brussels, Belgium, involving Crohn's disease drug Cimzia (certolizumab pegol), a tumor necrosis factor blocker.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.